Graticule
Graticule is a healthcare technology company focused on early cancer detection through advanced diagnostic tools.
Profile
Develops blood tests for early detection of multiple cancer types.
Graticule is a healthcare technology company focused on early cancer detection through advanced diagnostic tools. The company has gained attention for its flagship product, Galleri, a multi-cancer early detection (MCED) test designed to identify multiple cancer types from a single blood sample. In Q1 2026, Graticule reported Galleri revenue growth of 37% year-over-year to $39.8 million, with test volume increasing 50% to over 56,000.
Despite this growth, the company posted a net loss of $93.2 million for the quarter, though this represented a 12% improvement from the prior year. Graticule's financial position includes $823.1 million in cash and short-term marketable securities as of March 2026. The company is actively expanding access to Galleri, including a planned integration with Epic's electronic health record platform by late 2026.
Graticule's PMA application for Galleri was submitted to the FDA in January 2026 and is under review, supported by data from the PATHFINDER 2 and NHS-Galleri trials. The company's focus on commercialization and regulatory milestones positions it as a key player in the emerging MCED market, though profitability remains a challenge.
Who buys this
- Healthcare providers ordering diagnostic tests
- Health systems integrating MCED into clinical workflows
- Patients seeking early cancer detection
- Employers offering wellness programs
- Research institutions participating in clinical trials
Strengths and what to watch
Strengths
- Strong commercial growth with 50% year-over-year test volume increase
- Strategic EHR integration with Epic expected to expand market access
- Large-scale clinical validation through NHS-Galleri trial with 140,000 participants
Watch for
- Regulatory risk as Galleri's PMA application undergoes FDA review
- Significant quarterly losses ($93.2M in Q1 2026) despite revenue growth
- Competition in MCED space from established diagnostic companies
Recent moves
Key Information
- Founded
- 2020
- Headquarters
- Newton, MA. What
Frequently Asked Questions
What is Graticule's Galleri test?
Galleri is a multi-cancer early detection (MCED) blood test developed by Graticule. It screens for multiple cancer types from one blood sample, aiming to identify cancers earlier than traditional methods. The test reported 56,000 uses in Q1 2026, with 50% year-over-year growth in test volume.
How is Graticule performing financially?
Graticule reported $39.8 million Q1 2026 revenue, a 37% annual increase, but posted a $93.2 million net loss. The company holds $823.1 million in cash reserves. Test volume grew 50% year-over-year, showing commercial traction despite ongoing profitability challenges in the emerging MCED market.
Is Galleri FDA approved?
Graticule submitted Galleri's Premarket Approval (PMA) application to the FDA in January 2026. The review is ongoing, supported by data from PATHFINDER 2 and the NHS-Galleri trial involving 140,000 participants. Approval would significantly expand clinical use of this multi-cancer detection blood test.
How accurate is the Galleri cancer test?
While specific accuracy metrics aren't detailed here, Galleri's clinical validation includes the large-scale NHS-Galleri trial with 140,000 participants. The test's growing adoption (56,000 tests in Q1 2026) and 50% volume growth suggest healthcare providers find value in its multi-cancer detection capabilities.
When will Galleri integrate with Epic EHR?
Graticule plans to integrate Galleri with Epic's electronic health record platform by late 2026. This strategic move aims to streamline test ordering and results delivery, potentially expanding access to the multi-cancer detection test within health systems using Epic's widely adopted EHR software.
Who uses Graticule's cancer detection tests?
Galleri serves healthcare providers ordering tests, health systems integrating MCED into workflows, patients seeking early detection, employers offering wellness programs, and research institutions conducting trials. The test's 50% volume growth indicates broadening adoption across these segments despite being in the early commercialization phase.
Sources
- grail.com — Q1 2026 financial results and Galleri performance metrics
- www.pwc.com — Context on AI investment trends affecting healthcare M&A
- imaa-institute.org — M&A market context
- investor.crowncastle.com — Comparative Q1 2026 financial reporting context